Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab · Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
Primary and study completion pushed from Jun 14, 2027 to Nov 30, 2028
University of California, IrvinePhase 1 NCT05334329 Registry history of NCT05334329 on ClinicalTrials.gov (opens the registry)